ArQule, Daiichi report results of tivantinib trial

01/14/2013 | Reuters

ArQule and Daiichi Sankyo's tivantinib, in combination with older cancer drugs irinotecan and cetuximab, did not demonstrate a statistically significant difference versus placebo in improving progression-free survival among patients with refractory or relapsed colorectal cancer during a mistage trial. The partners will talk with medical experts in colorectal cancer about how to proceed, and the drug also is in development for liver cancer.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR